- SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein concentrating on ASGR1
- First a part of two-part Part 1 trial begins in wholesome volunteers
SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Firm”) (Nasdaq: SRZN), a clinical-stage firm pioneering focused therapeutics that selectively activate the Wnt pathway for tissue restore and regeneration, at present introduced that the primary topic has been dosed in its two-part Part 1 scientific trial for SZN-043 which is in growth for the potential remedy of extreme alcoholic hepatitis.
The Part 1, randomized, single and a number of ascending dose research will consider the protection, pharmacokinetics and exercise of SZN-043. The primary a part of the trial will consider single doses of SZN-043 administered by way of intravenous injection or infusion in wholesome volunteers, progressing from 3 mg by means of 30 mg. The second half will consider a number of ascending doses of SZN-043 for a interval of 4 weeks in sufferers with a documented historical past of liver cirrhosis and a Youngster-Pugh rating between 5 and seven on the 2 highest dose ranges tolerated partially 1. The first endpoint of the trial is security and tolerability of SZN-043 and secondary outcomes embody pharmacokinetics, pharmacodynamic markers in addition to prevalence of Anti-Drug Antibodies (ADA).
“We’re gaining momentum as a scientific group with two research now enrolling topics, and each reaching the clinic forward of schedule,” stated Craig Parker, President and Chief Govt Officer of Surrozen. “Our crew has remained diligently centered on making use of our Wnt analysis and platforms whereas quickly advancing these uniquely engineered antibodies. We look ahead to persevering with to construct on this momentum with SZN-043 and SZN-1326, in addition to our research- and discovery-stage packages.”
Trudy Vanhove, M.D., Ph.D., Chief Medical Officer of Surrozen, added: “Extreme alcoholic hepatitis has a 30% mortality at 90 days and there stays a big want for brand new acute remedy choices for these sufferers. As a primary step in the direction of testing SZN-043 in extreme AH sufferers, we’re evaluating security and pharmacokinetics of SZN-043 in wholesome volunteers and sufferers with cirrhosis, a typical function in sufferers with extreme AH. We will even be evaluating pharmacodynamic markers of Wnt activation, hepatocyte perform and hepatocyte proliferation.”
SZN-043 for Extreme Alcoholic Hepatis
SZN-043 is the primary growth candidate utilizing Surrozen’s SWEETS™ know-how which is designed to imitate the regenerative properties of the protein R-Spondin by enhancing Wnt signaling in a cell-targeted method. In a number of preclinical animal fashions of liver harm and fibrosis, SZN-043 has been proven to selectively activate Wnt signaling within the liver, stimulate transient hepatocyte proliferation, enhance liver perform and scale back fibrosis with no treatment-related opposed results noticed in 4-week GLP toxicology evaluations in mice and NHPs. Surrozen is growing SZN-043 for extreme liver illnesses, initially specializing in extreme alcoholic hepatitis. The primary topic within the Part 1 scientific research of SZN-043 was dosed in June, and the trial is posted to the Australian New Zealand Scientific Trial Registry here.
About Wnt Signaling
Wnt signaling performs key roles within the management of growth, homeostasis, and regeneration of many important organs and tissues, together with liver, gut, lung, kidney, retina, central nervous system, cochlea, bone and others. Modulation of Wnt signaling pathways has potential for remedy of degenerative illnesses and tissue accidents. Surrozen’s platform and proprietary applied sciences have the potential to beat the constraints in pursuing the Wnt pathway as a therapeutic technique.
About Surrozen
Surrozen is a biotechnology firm discovering and growing drug candidates to selectively modulate the Wnt pathway. Surrozen is growing tissue-specific antibodies designed to interact the physique’s present organic restore mechanisms with potential software throughout a number of illness areas, together with inflammatory bowel illness, hepatitis, eye illnesses, listening to loss, lung and airway illnesses, and sure neurological problems. For extra data, please go to surrozen.com.
Ahead Trying Statements
This press launch incorporates sure forward-looking statements inside the that means of the federal securities legal guidelines. Ahead-looking statements usually are accompanied by phrases corresponding to “will,” “plan,” “potential,” “count on,” “advance,” “consequence,” “endpoint,” “might,” or the destructive of those phrases and comparable expressions that predict or point out future occasions or developments or that aren’t statements of historic issues. These forward-looking statements embody, however aren’t restricted to, statements concerning Surrozen’s discovery, analysis and growth actions, particularly its growth plans for its product candidates SZN-1326, SZN-043, and SZN-413, together with anticipated scientific growth timelines, and the potential for such product candidates for use to deal with human illness. These statements are primarily based on numerous assumptions, whether or not or not recognized on this press launch, and on the present expectations of the administration of Surrozen and aren’t predictions of precise efficiency. These forward-looking statements are supplied for illustrative functions solely and aren’t meant to function, and should not be relied on as, a assure, an assurance, a prediction, or a definitive assertion of reality or likelihood. Precise occasions and circumstances are tough or unimaginable to foretell and can differ from assumptions. Many precise occasions and circumstances are past the management of Surrozen. These forward-looking statements are topic to various dangers and uncertainties, together with the initiation, price, timing, progress and outcomes of analysis and growth actions, preclinical or and scientific trials with respect to SZN-1326, SZN-043, SZN-413, and potential future drug candidates; Surrozen’s means to determine, develop and commercialize drug candidates; Surrozen’s means to efficiently full preclinical and scientific research for SZN-1326, SZN-043, SZN-413, or different future product candidates; the consequences that come up from volatility in international financial, political, regulatory and market situations, which can be adversely affected by the battle between Russia and Ukraine; the continuing coronavirus (COVID-19) pandemic; and all different elements mentioned in our Annual Report on Type 10-Ok for the 12 months ended December 31, 2021 underneath the heading “Danger Elements” and different paperwork Surrozen has filed, or will file, with the Securities and Change Fee. If any of those dangers materialize or our assumptions show incorrect, precise outcomes might differ materially from the outcomes implied by these forward-looking statements. There could also be further dangers that Surrozen presently doesn’t know, or that Surrozen presently believes are immaterial, that might additionally trigger precise outcomes to vary from these contained within the forward-looking statements. As well as, forward-looking statements mirror Surrozen’s expectations, plans, or forecasts of future occasions and views as of the date of this press launch. Surrozen anticipates that subsequent occasions and developments will trigger its assessments to vary. Nevertheless, whereas Surrozen might elect to replace these forward-looking statements sooner or later sooner or later, Surrozen particularly disclaims any obligation to take action, besides as required by legislation. These forward-looking statements shouldn’t be relied upon as representing Surrozen’s assessments of any date subsequent to the date of this press launch. Accordingly, undue reliance shouldn’t be positioned upon the forward-looking statements.
Media Contacts:
CanaleComm
Ian Stone, Managing Director
Tel.: (619) 518-3518
E mail: ian.stone@evokegroup.com
Ingrid Mezo, Account Director
Tel.: (301) 473-2881
E mail: ingrid.mezo@evokegroup.com
Investor Contact:
E mail: Investorinfo@surrozen.com
